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Abstract
Background/Aims: To determine the optimal dose of 
LB03002, a sustained-release, once-weekly formulation of 
recombinant human growth hormone (rhGH), and to com-
pare its efficacy and safety with daily rhGH in children with 
idiopathic short stature (ISS). Methods: This multicenter, ran-
domized, open-label, phase II study included GH-naïve, pre-
pubertal children with ISS, randomized to receive daily rhGH 
0.37 mg/kg/week (control, n = 16), LB03002 0.5 mg/kg/week 
(n = 14), or LB03002 0.7 mg/kg/week (n = 16). The primary 
endpoint was height velocity (HV) change at week 26. Re-
sults: At week 26, the least square (LS) means for HV change 
(cm/year) with control, LB03002 0.5 mg/kg/week, and 
LB03002 0.7 mg/kg/week were 5.08, 3.65, and 4.38, and the 
LS means for the change in height standard deviation score 
were 0.65, 0.49, and 0.58, respectively. The lower bound of 
the 90% confidence interval for the difference between 
LB03002 0.7 mg/kg/week and the control in the LS mean for 
HV change (–1.72) satisfied the noninferiority margin (–1.75). 
Adverse events were generally mild and short-lived. Conclu-
Clinical trial registration number: ClinicalTrials.gov NCT02042170.
This article is licensed under the Creative Commons Attribution-
NonCommercial-NoDerivatives 4.0 International License (CC BY-
NC-ND) (http://www.karger.com/Services/OpenAccessLicense). 
Usage and distribution for commercial purposes as well as any dis-
tribution of modified material requires written permission.
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sion: A once-weekly regimen of LB03002 0.7 mg/kg demon-
strated noninferiority to the daily regimen of rhGH 0.37 mg/
kg/week in terms of HV increments. LB03002 was well toler-
ated and its safety profile was comparable with that of daily 
rhGH. © 2018 The Author(s)
Published by S. Karger AG, Basel
Introduction
With the progress in molecular biotechnology, en-
abling large-scale production of recombinant human 
growth hormone (rhGH), many studies have been con-
ducted to evaluate the use of rhGH in conditions present-
ing short stature but without classical growth hormone 
deficiency (GHD), such as chronic renal failure, Turner 
syndrome, Prader-Willi syndrome, small for gestational 
age, and idiopathic short stature (ISS). Among these, ISS 
is a quite frequently encountered condition as the spe-
cific causes of short stature are determined only for a 
small proportion (e.g., approximately 5–20%) of children 
[1–3]. ISS is generally defined as the condition character-
ized by a height below –2.0 standard deviation score 
(SDS) for the corresponding age and sex, with no evi-
dence of an underlying disorder [4, 5]. Although the use 
of rhGH in children with ISS remains controversial, a 
number of randomized controlled studies confirmed that 
compared with placebo or no treatment, rhGH has a pos-
itive effect on short-term growth and final adult height in 
children with ISS [4, 6–11].
 However, most of the available rhGH products require 
subcutaneous injection 6 or 7 times a week for the entire 
treatment period, which may reduce the treatment com-
pliance. Thus, several technologies were used in an at-
tempt to develop longer-acting rhGH formulations [12]. 
LB03002 (EutropinPlus inj.) is a once-weekly sustained-
release formulation of rhGH manufactured using geneti-
cally modified Saccharomyces cerevisiae and contained in 
sodium hyaluronate microparticles suspended in medi-
um-chain triglycerides prior to injection [13]. The efficacy 
and safety of LB03002 were confirmed in children and 
adults with GHD [14–16]. Up to date, however, there is no 
evidence confirming the efficacy of the once-weekly for-
mulation in ISS patients. The aim of this study was to in-
vestigate the efficacy and safety of LB03002, and to select 
its optimal dose in children with ISS. As a comparator, we 
used Eutropin inj., the agent sharing the same expression 
system with LB03002 but in the immediate-release formu-
lation (daily rhGH), approved in South Korea for the 
treatment of ISS, GHD, and other indications.
Subjects, Materials, and Methods
Study Design and Principle
This was a phase II, multicenter, randomized, active-controlled 
(daily rhGH as control), open-label, dose-finding study (between 
0.5 mg/kg/week and 0.7 mg/kg/week). The lower dose was the ap-
proved dose for GHD, considered to be a comparable dose level to 
that of the comparator (0.37 mg/kg/week), whereas the higher 
dose was the maximum dose within the safety margin provided by 
the animal toxicity study. All the procedures were carried out ac-
cording to the Declaration of Helsinki, Good Clinical Practice, and 
standard operating procedures of the Sponsor. The study protocol 
was reviewed and approved by the Ministry of Food and Drug 
Safety of Korea and the institutional review board of each investi-
gational site. Patients and their parents or legal guardians were 
provided with a full explanation of the purpose and nature of all 
study procedures, and parental written informed consent was ob-
tained before the screening. Additionally, informed consent was 
sought from all the patients who were able to read and write in 
Korean (usually ≥7 years of age). The study was registered at 
ClinicalTrials.gov (identifier: NCT02042170).
Patients
Eligible patients were prepubertal children aged at least 4 years 
and diagnosed with ISS with bone ages (BA) less than 9 and 11 
years for girls and boys, respectively. ISS was diagnosed whenever 
all of the following conditions were met: (i) height ≤3rd percentile 
for age and sex; (ii) normal GH secretion confirmed based on GH 
concentration ≥10 ng/mL in at least one stimulation test [17]; (iii) 
normal body proportion without skeletal dysplasia; and (iv) lack 
of pathological abnormalities that might inhibit growth. Children 
with GHD or other causes of short stature, including Prader-Wil-
li syndrome, Russel-Silver syndrome, Seckel syndrome, or small 
for gestational age, were excluded from the study, along with the 
patients with some other comorbidities, such as primary hypothy-
roidism, adrenal insufficiency, hypogonadism, diabetes, malig-
nancy, or closed epiphyses. In addition, children treated with sex 
hormones, steroids, aromatase inhibitors, thyroxine (other than 
administered at a stable dose for 4 weeks or more), or medications 
for attention deficit hyperactivity disorder were also excluded.
Study Procedure
Eligible patients were randomized to one of the three arms (dai-
ly rhGH 0.37 mg/kg/week, LB03002 0.5 mg/kg/week, or LB03002 
0.7 mg/kg/week) in a 1: 1: 1 ratio with stratification according to the 
sex and age (≥7 years or < 7 years). Study visits were scheduled at 
the baseline, week 13, week 26, and week 30. One week after the 
baseline visit and at week 13, the study staff contacted the patients’ 
parents to assure their compliance to activities set out in the con-
sent form. Daily rhGH (control) was given 6 times per week at 
equally divided doses corresponding to a total weekly dose of 0.37 
mg/kg, whereas the weekly rhGH (LB03002 0.5 mg/kg or 0.7 mg/
kg) was administered once a week at the dose assigned to a given 
group. Injections were given subcutaneously by the patients’ par-
ents or legal guardians at bedtime for 26 weeks. Injection site reac-
tions were recorded in the diary cards. In order to assess the treat-
ment compliance, the prescribed dose and the number of vials dis-
pensed, used, and returned were counted and recorded at the study 
site. The following parameters were determined at the baseline or 
during the screening, at week 13 and 26: height, weight, Tanner 
Hwang/Lee/Lee/Yoo/Lee/Suh/Ko/Chung/
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pubertal stage, thyroid function parameters, insulin-like growth 
factor I (IGF-I), IGF-I-binding protein 3 (IGFBP-3), complete 
blood count, blood chemistry, and urinalysis. Height, weight, 
IGF-I, and IGFBP-3 were measured again at the follow-up visit 
(week 30). An X-ray to determine BA and the measurement of 
anti-rhGH antibodies were performed both at screening and at 
week 26. BA was estimated using the Greulich-Pyle method by two 
independent pediatric endocrinologists who were blinded to the 
patients’ demographics and assigned treatments. Blood samples 
for the pharmacokinetic (PK) and pharmacodynamic (PD) analy-
ses of rhGH were taken at baseline from all patients. For patients 
randomized to the LB03002 groups, additional blood samples for 
PK and PD analyses were obtained at two time points, at 36 h and 
at 7 days after the last injection (26th dosing). 
Assessment of Study Endpoints
The primary endpoint was the change in annualized height ve-
locity (HV) at week 26 from baseline. HV was calculated using the 
following formula: HV (cm/year) = (last height measurement – 
height at baseline) / (number of days between the first injection 
and last height measurement) × 365. Standing height was mea-
sured three times using a calibrated stadiometer at each visit, and 
the mean values were used. To calculate the baseline HV, the base-
line height and height measured at least 6 months before the base-
line were used. The list of secondary endpoints included HV at 
week 13; height, IGF-I, IGF-I SDS, IGFBP-3, and IGFBP-3 SDS at 
week 13 and week 26; and height SDS for BA and chronological 
age (CA), BA, and ΔBA/ΔCA at week 26. The list of PK and PD 
parameters for LB03002 included the levels of human growth hor-
mone (hGH), IGF-I, and IGFBP-3. Adverse events, injection site 
reactions, laboratory results, and anti-rhGH antibody level were 
considered as safety endpoints.
Assays
Serum levels of hGH, IGF-I, and IGFBP-3 were measured by 
chemiluminescence immunoassay using Immulite 2000 Immuno-
assay System (Siemens Healthcare Diagnostics Inc., Germany) at 
Seoul Medical Science Institute (SCL), South Korea, and anti-hGH 
antibodies were quantified using a radio-precipitation assay at the 
University of Leipzig, Germany. All assays have been validated for 
their limit of detection and quantification, precision, linearity, and 
recovery. Other laboratory parameters, such as functional parame-
ters of the thyroid, complete blood count, blood chemistry, and uri-
nalysis were determined at the SCL with an aid of validated assays.
Statistical Analysis
In order to select the optimal dose of LB03002, a noninferior-
ity test for the change in HV at week 26 was carried out with the 
LB03002 groups against the daily rhGH group. Assuming a stan-
dard deviation (SD) of 1.7 cm/year for the change in HV and non-
Daily rhGH
0.37 mg/kg/week
(n = 16)
LB03002
0.5 mg/kg/week
(n = 14)
Randomized
Screened
LB03002
0.7 mg/kg/week
(n = 16)
Not eligible = 4
Consent withdrawal = 1
Treatm
ent for 26 weeks
Day 0
Week 30
4 week F/U
• Completed = 16
• Safety set = 16
• FAS = 16
• PPS = 14
• Completed = 14
• Safety set = 14
• FAS = 14
• PPS = 14
• Completed = 16
• Safety set = 16
• FAS = 16
• PPS = 14
Fig. 1. Disposition of the patients. A total of 51 children with ISS were screened; 46 were randomized; and 46 
completed the study. All patients were included in the analysis. After excluding 4 patients with major protocol 
deviations, 42 were included in the PPS, the main analysis population for efficacy evaluation.
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inferiority margin of 1.75 cm/year, 12 patients per group were con-
sidered sufficient to achieve 80% power to detect the between-
group difference with a one-sided significance level of 5%. The 
enrollment target was approximately 45 patients (15 per group) to 
accommodate 20% drop-out and protocol deviations. The prima-
ry endpoint was analyzed using the ANCOVA model with baseline 
HV covariates and treatment group, age (≥7 or < 7 years), and sex 
as fixed variables; two-sided 90% confidence interval (CI) for the 
least square (LS) mean difference was calculated, and if the lower 
bound of the CI was greater than –1.75, noninferiority of LB03002 
to daily rhGH was to be declared. The same ANCOVA model was 
used for the secondary endpoints. Missing values for the primary 
endpoint were replaced by the last available data according to the 
last-observation-carried-forward approach. For the computation 
of height SDS, the following equation was used referencing the 
power in the Box-Cox transformation (L), median (M), and coef-
ficient of variation (S) values from the growth standards for Ko-
rean children and adolescents [18]: height SDS = [power (mea-
sured height / M, L) – 1] / L × S. The SDS for IGF-I and IGFBP-3 
were computed using the following equation: SDS = (measured 
value – mean population value) / SD of population value [19]. 
Treatment compliance was calculated by the following formula: 
(total number of vials used) / {(prescribed dose per injection × 
26) / 1.2} for LB03002 groups, and (total number of vials used) / 
{(prescribed dose per injection × 6 × 26) / 0.8} for the comparator 
group. All treated patients who were randomized and received the 
study drug at least once were included in the safety analysis; treat-
ed patients with at least one height measurement after the baseline 
were included in the full analysis set (FAS), and patients without 
any major protocol deviations, such as treatment compliance 
< 80% or violation of eligibility criteria, were included in the per-
protocol set (PPS), the main population for the efficacy evaluation. 
All statistical analyses were performed using SAS® software, ver-
sion 9.2 (SAS Institute, Cary, NC, USA). 
Results
Patient Disposition and Characteristics
From March 2014 to March 2015, 46 out of 51 screened 
patients were randomized and completed the study (Fig. 1). 
Except for 1 patient (daily rhGH group) whose treatment 
compliance was 79%, all other patients reached more than 
80% of treatment compliance. All randomized patients 
were included in the safety and FAS analyses. The PPS in-
cluded 42 patients; another 4 patients were not included 
due to major protocol deviations, namely study drug com-
pliance < 80% (n = 1), dosage error (n = 2), and delay in 
initiation of the study treatment (n = 1). All patients were 
naïve to rhGH treatment, born at normal gestational ages 
(37–41 weeks), and presented with Tanner stage I. Mean 
height SDS for CA in all groups was less than –2, with a 
Table 1. Patient demographics at baseline (PPS)
Daily rhGH
0.37 mg/kg/week
(n = 14)
LB03002
0.5 mg/kg/week
(n = 14)
LB03002
0.7 mg/kg/week
(n = 14)
Age, years 5.86 (1.29) 5.36 (1.22) 6.07 (1.54)
Male, n 10 9 10
Female, n 6 5 6
Birth weight, kg 3.01 (0.3) 3.11 (0.29) 3.01 (0.28)
Weight, kg 17.46 (2.42) 16.61 (2.43) 18.94 (6.84)
Mid-parental height, cm 162.55 (7.45) 164.44 (9.29) 164.39 (7.44)
Height, cm 105.88 (6.06) 104.07 (6.23) 107.47 (8.41)
Height SDS for CA –2.25 (0.3) –2.28 (0.29) –2.28 (0.37)
Height SDS for CA ≤ –2.25, n 5 8 6
BA, years 5.6 (1.53) 4.72 (0.82) 5.49 (1.92)
Height SDS for BA –1.35 (1.28) –0.69 (1.32) –0.8 (1.57)
Height velocity, cm/year 6.24 (1.6) 6.11 (1.3) 5.51 (0.94)
Peak GH plasma conc., ng/mL 17.55 (10, 85.7) 17.15 (10.6, 41) 15.1 (10.1, 26.4)
IGF-I, ng/mL 121 (51.4, 212) 128 (50.2, 206) 105 (56.1, 166)
IGF-I SDS –0.67 (–1.39, 0.39) –0.8 (–2.03, 0.63) –1.3 (–2.06, 0.15)
IGFBP-3, ng/mL 3,660 (2,200, 4,980) 3,490 (2,450, 5,910) 3,655 (2,440, 5,040)
IGFBP-3 SDS 2.2 (–0.17, 5.15) 2.47 (–0.11, 8.9) 1.89 (0, 5.27)
Continuous variables are presented with mean (SD) except peak GH plasma concentration, blood levels of 
IGF-I and IGFBP-3, and SDS of IGF-I and IGFBP-3, all of which are presented with median (min, max). Mid-
parental height (MPH) (cm) was calculated using the following formula: MPH (for boys) = {paternal height + 
(maternal height + 13)}/2; MPH (for girls) = {(paternal height – 13) + maternal height}/2.
Hwang/Lee/Lee/Yoo/Lee/Suh/Ko/Chung/
Jin/Shin/Han/Han/Kim
Horm Res Paediatr 2018;90:54–6358
DOI: 10.1159/000489262
range of –3.01 to –1.68, and the proportion of extremely 
short patients (height SDS ≤–2.25) amounted to 45% 
(PPS). However, HV was mostly normal for the corre-
sponding age group; GH secretion after the provocation 
test was normal (≥10 ng/mL) [17], and IGF-I and IGFBP-3 
levels were within the reference ranges. The treatment 
groups were well balanced in terms of demographic and 
clinical characteristics (Table 1), yet the mean BA (years) 
of the LB03002 0.5 mg/kg/week group was significantly 
lower than that of the daily rhGH group (4.72 vs. 5.93, p = 
0.041) in the FAS but not in the PPS (4.72 vs. 5.6, p = 0.107).
Efficacy Results
At week 26, a significant increase in HV was docu-
mented in patients from all three groups (Fig. 2). No sta-
tistically significant difference in the actual mean HV 
change was found between each LB03002 dose group and 
the daily rhGH group (control). In the HV ANCOVA, the 
LS mean of the change in HV at week 26 in the control, 
LB03002 0.5 mg/kg/week, and LB03002 0.7 mg/kg/week 
group was 5.08, 3.65, and 4.38, respectively. The 90% CI 
for the LS mean of the change in HV versus control at 
week 26 was –2.43 to –0.44 and –1.72 to 0.33 for LB03002 
0.5 mg/kg/week and LB03002 0.7 mg/kg/week, respective-
ly. Thus, only the LB03002 0.7 mg/kg/week group demon-
strated noninferiority to control. Also, the FAS analysis 
yielded the same conclusion (lower bound of the 90% CI 
for the change in HV vs. control was –2.1 for LB03002 0.5 
mg/kg/week, and –1.21 for LB03002 0.7 mg/kg/week). 
The ANCOVA interaction test showed that the change in 
HV was independent of the baseline HV, age, or sex. Con-
sistent with the HV values, also height and height SDS for 
CA increased significantly in all three groups (p < 0.001), 
and the degree of changes at week 26 for LB03002 0.7 mg/
kg/week group and control group were essentially similar 
(Table 2). The lower dose of LB03002 (0.5 mg/kg/week) 
consistently showed inferior response to the control at 
week 26 in terms of changes in height and height SDS in 
addition to the change in HV (see online suppl. Table 1; 
see www.karger.com/doi/10.1159/000489262 for all on-
line suppl. material). While a post-treatment increase in 
BA was observed as well, it was not too advanced for CA, 
as indicated by the nonsignificant change in the BA ad-
vancement index (ΔBA/ΔCA) at week 26. Irrespective of 
the treatment, the clinical changes mentioned above coex-
isted with an increase in pharmacodynamic parameters, 
IGF-I and IGFBP-3 (Table 2). However, a significant in-
crease from baseline was observed solely in the controls 
and in the LB03002 0.7 mg/kg/week group; these two 
groups did not differ significantly in terms of the degree 
of post-treatment change in IGF-I and IGFBP-3 levels.
PK/PD Results
Baseline blood concentrations of hGH in both LB03002 
groups were similar, with individual values ranging from 
0.05 to 18.5 ng/mL. When blood samples were collected at 
36 h after the 26th dosing, both groups showed a significant 
increase in the hGH level. This parameter increased in a 
dose-dependent manner, with a median (min, max) hGH 
level (ng/mL) equal to 15.15 (1.16, 38.8) and 40.55 (7.42, 
83) for the 0.5 mg/kg/week and 0.7 mg/kg/week group, re-
spectively (p < 0.001). At 7 days after the 26th dosing, blood 
concentrations of hGH in nearly half of the patients were 
lower than 5 ng/mL, and no significant between-group dif-
ferences were found in hGH levels (p = 0.467). Also, IGF-I 
and IGFBP-3 concentrations at 36 h after the 26th dosing 
were significantly higher than at the baseline (p < 0.001), 
without statistically significant between-group differences 
in either parameter (see online suppl. Table 2). 
Safety Results
During the 30-week study period, 7 (44%), 9 (64%), 
and 10 (63%) patients from the control, LB03002 0.5 mg/
kg/week, and LB03002 0.7 mg/kg/week groups experi-
20
15
10
5
0
HV
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m
/y
ea
r
0 26
Week
+ + +
+
+ +
 Daily rhGH 0.37 mg/kg/week
■ LB03002 0.5 mg/kg/week
■ LB03002  0.7 mg/kg/week
Fig. 2. Annualized height velocity (PPS). Before initiating rhGH 
treatment, median HV (cm/year) across three groups was less than 
6 cm/year. A 6-month treatment resulted in significant increases 
in HV (p < 0.001), with median changes (cm/year) of 4.85, 3.1, and 
4.69 in the daily rhGH, LB03002 0.5 mg/kg/week, and LB03002 
0.7 mg/kg/week groups, respectively. The top and bottom of the 
box represent the 25th and 75th percentiles, the horizontal line 
inside the box represents the median, the symbol (+) represents 
mean, and the whiskers represent 5th and 95th percentile.
Use of Weekly GH in Idiopathic Short 
Stature
59Horm Res Paediatr 2018;90:54–63
DOI: 10.1159/000489262
enced 12, 28, and 23 adverse events, respectively (Table 
3). The adverse events were mostly mild except 1 severe 
and 3 moderate events reported in the LB03002 0.5 mg/
kg/week group. Eight adverse events were related with the 
rhGH treatment, mostly with LB03002 0.5 mg/kg/week 
(n = 7) and LB03002 0.7 mg/kg/week (n = 1): injection site 
pruritus (n = 1), acute tonsillitis (n = 1), bronchitis (n = 
2), acute otitis media (n = 1), upper respiratory tract in-
fection (n = 1), atopic dermatitis (n = 1), and rash (n = 1) 
as preferred terms. Two serious adverse events (meningi-
tis and thermal burn) were reported with LB03002 0.5 
mg/kg/week; however, neither had any causal relation-
ship with the treatment. 
Regarding injection site reactions (warmth, erythema, 
and swelling), swelling occurred most frequently, and the 
patients receiving LB03002 experienced local reactions 
more frequently than those administered daily rhGH 
(Table 4). However, the intensity was generally tolerable, 
and the reactions were mostly resolved within 6 days (Ta-
ble 4). The severity of pain, marked on the 150-mm vi-
sual analogue scale (VAS), did not exceed half of the VAS 
length and showed a decreasing tendency with repeated 
injections. 
When looking at the individual subject’s IGF-I SDS, 10 
and 11 subjects in the LB03002 0.5 mg/kg/week and 
LB03002 0.7 mg/kg/week group, respectively, had IGF-I 
greater than 2 SDS at 36 h after the last injection. How-
ever, the nonphysiological level of IGF-I was mostly nor-
malized at 7 days after the last injection (see online suppl. 
Fig. 1). No laboratory abnormalities were assessed to be 
clinically relevant. None of the patients tested positive for 
anti-hGH antibodies at the baseline, whereas at week 26, 
anti-hGH antibodies were detected in 3 and 6 patients 
from the LB03002 0.5 mg/kg/week and 0.7 mg/kg/week 
group, respectively. The subgroup analysis demonstrated 
that the presence of anti-hGH antibodies did not affect 
the change in HV at week 26 or blood hGH concentration 
at 36 h after the 26th dosing (data not shown).
Table 2. Changes from baseline in efficacy endpoints (PPS)
Daily rhGH
0.37 mg/kg/week
(n = 14)
LB03002
0.5 mg/kg/week
(n = 14)
LB03002
0.7 mg/kg/week
(n = 14)
ΔHeight, cm
Week 13 2.77 (2.49, 3.05) 2.64 (2.37, 2.91) 2.54 (2.25, 2.82)
Week 26 5.53 (5.14, 5.92) 4.81 (4.43, 5.18) 5.19 (4.8, 5.59)
ΔHeight velocity, cm/year
Week 13 4.99 (3.92, 6.07) 4.62 (3.53, 5.71) 4.12 (3, 5.24)
Week 26 5.08 (4.35, 5.81) 3.65 (2.91, 4.39) 4.38 (3.63, 5.14)
ΔHeight SDS for CA
Week 26 0.65 (0.57, 0.74) 0.49 (0.4, 0.58) 0.58 (0.5, 0.67)
ΔHeight SDS for BA
Week 26 0.51 (0.32, 0.69) 0.45 (0.27, 0.64) 0.32 (0.14, 0.5)
ΔBA, years
Week 26 0.62 (0.48, 0.76) 0.55 (0.42, 0.69) 0.73 (0.6, 0.87)
ΔBA/ΔCA
Week 26 0.02 (0, 0.04) 0 (–0.02, 0.02) 0.03 (0.01, 0.05)
ΔIGF-I, ng/mL
Week 13 73.6 (40.43, 106.76) 24.89 (–7.92, 57.7) 50.79 (19.17, 82.4)
Week 26 92.3 (40.06, 144.55) 28.3 (–23.39, 79.99) 73.8 (23.99, 123.6)
ΔIGF-I SDS
Week 13 0.95 (0.43, 1.46) 0.35 (–0.16, 0.87) 0.87 (0.35, 1.4)
Week 26 1.3 (0.52, 2.08) 0.41 (–0.36, 1.19) 1.12 (0.33, 1.91)
ΔIGFBP-3, ng/mL
Week 13 681.03 (324.66, 1037.41) 149.87 (–214.75, 514.49) 379.84 (26.14, 733.53)
Week 26 806.84 (453.95, 1159.73) 276.97 (–84.09, 638.03) 622.96 (272.72, 973.2)
ΔIGFBP-3 SDS
Week 13 1.34 (0.55, 2.13) 0.32 (–0.49, 1.12) 0.87 (0.08, 1.65)
Week 26 1.69 (0.93, 2.46) 0.62 (–0.15, 1.4) 1.31 (0.55, 2.06)
Data are changes from baseline at each time point, presented as LS mean (90% CI).
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Discussion
In this open-label, randomized study targeting Korean 
children diagnosed with ISS, LB03002 0.7 mg/kg/week 
was noninferior to daily rhGH administered 6 times per 
week at the total dose of 0.37 mg/kg/week. Both products 
were well tolerated without significant adverse reactions.
Despite the use of thin needles and alternative delivery 
routes, daily administration of rhGH may be inconve-
nient. Owing to the long duration of the therapy, this may 
negatively affect patient’s or caregiver’s adherence to the 
treatment schedules. Indeed, one previous study demon-
strated a significant difference in the mean treatment du-
ration between good compliance and moderate-poor 
compliance groups (2.78 vs. 3.78 years, p = 0.001) [20]. 
Moreover, available evidence shows that poor adherence 
to the rhGH regimen is quite frequent and may negative-
ly affect the treatment outcome [21–24]. Even though 
there is no evidence to prove a better adherence with long-
acting rhGH than with daily rhGH, reducing the dosing 
frequency to once a week, theoretically, can be considered 
a benefit to patients and their caregivers, if proved to be at 
least as safe and effective as daily rhGH. Based on this 
premise, we conducted a randomized study in children 
with ISS to select the optimal dose of LB03002; the safety 
and efficacy of this agent, administered at 0.5 or 0.7 mg/
kg/week, were compared with respective characteristics of 
daily rhGH given at a labeled dose for ISS patients (0.37 
mg/kg/week). The first dosage regimen of LB03002 (0.5 
mg/kg/week) is the recommended dose of this product for 
Table 3. List of adverse events
Preferred term Daily rhGH
0.37 mg/kg/week
(n = 16) 
LB03002
0.5 mg/kg/week
(n = 14)
LB03002
0.7 mg/kg/week
(n = 16)
Ear pain 0 (0) 1 (1) 0 (0)
Dyspepsia 0 (0) 0 (0) 1 (1)
Enteritis 0 (0) 1 (1) 2 (2)
Vomiting 0 (0) 1 (1) 0 (0)
Injection site pruritus 0 (0) 1 (1) 1 (1)
Acute tonsillitis 0 (0) 1 (1) 1 (2)
Bronchitis 0 (0) 2 (4) 0 (0)
Folliculitis 0 (0) 1 (1) 0 (0)
Furuncle 1 (1) 0 (0) 0 (0)
Hordeolum 1 (1) 0 (0) 1 (1)
Laryngitis 1 (1) 0 (0) 0 (0)
Meningitis 0 (0) 1 (1)a 0 (0)
Nasopharyngitis 3 (3) 1 (2) 2 (5)
Otitis externa 0 (0) 0 (0) 1 (1)
Acute otitis media 0 (0) 1 (1) 0 (0)
Pharyngitis 1 (1) 2 (2) 0 (0)
Tonsillitis 1 (1) 1 (1) 0 (0)
Tracheitis 0 (0) 0 (0) 1 (1)
Upper respiratory tract infection 1 (1) 3 (6) 1 (2)
Varicella 0 (0) 0 (0) 1 (1)
Foot fracture 1 (1) 0 (0) 0 (0)
Laceration 0 (0) 1 (1)a 0 (0)
Thermal burn 0 (0) 1 (1)b 0 (0)
Arthralgia 0 (0) 0 (0) 1 (1)
Headache 0 (0) 0 (0) 1 (4)
Balanoposthitis 0 (0) 1 (1) 0 (0)
Allergic rhinitis 1 (1) 0 (0) 0 (0)
Atopic dermatitis 0 (0) 1 (1)a 1 (1)
Rash 1 (1) 1 (1) 0 (0)
Numbers before parentheses represent the number of patients experiencing each adverse event, whereas those 
in the parentheses represent the total number of each event. a Moderate in intensity. b Severe in intensity; the rest 
of the events were mild in intensity.
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pediatric GHD patients. For the second regimen, a higher 
dosage (0.7 mg/kg/week) than the one approved for GHD 
was to be tested based on the evidence that ISS patients 
show worse growth response to rhGH therapy than pa-
tients with severe GHD [10]. High-dose rhGH therapy 
(0.7 mg/kg/week, daily) had previously been demonstrat-
ed to be effective and safe in GH-deficient adolescents 
who were most growth-retarded at the onset of puberty 
[25]. Finally, the PK/PD profiles of LB03002 administered 
at either 0.5 or 0.7 mg/kg/week were shown to be suitable 
for a long-term treatment of children with GHD [16, 26]. 
Although the PK/PD profiles of LB03002 in children with 
ISS were out of the scope of the present study, sparse data 
on the dynamics of hGH, IGF-I, and IGFBP-3 levels imply 
that they may be similar to those documented previously 
in GHD patients. The increase in hGH, IGF-I, and 
IGFBP-3 observed at 36 h after the last dose may imply 
that the patients were adequately exposed to LB03002, 
though a physiologically high level of IGF-I may be of con-
cern. Further, the return of hGH, IGF-I, and IGFBP-3 to 
their baseline levels at 7 days after the last dose may sug-
gest that repeated administration of LB03002 did not re-
sult in accumulation thereof.
In terms of the primary efficacy evaluation, adminis-
tration of either LB03002 (irrespective of the dose) or the 
comparator resulted in a significant increase in HV in ISS 
patients (p < 0.0001). The changes in HV documented in 
all three groups (3.65–5.08 cm/year) were comparable 
with the assumed effect size (3.99 cm/year) and the 1-year 
change observed in other studies [8, 27, 28]. Also, the 
Table 4. Number of patients with injection site reactions by maximal intensity
Daily rhGH
0.37 mg/kg/week
(n = 16)
LB03002
0.5 mg/kg/week
(n = 14)
LB03002
0.7 mg/kg/week
(n = 16)
Maximum intensity
Warmth
None 12 5 5
Mild 4 8 9
Moderate 0 1 2
Erythema
None 12 2 1
Mild (<5 mm) 3 5 4
Moderate (≥5 mm, <20 mm) 0 5 7
Severe (≥20 mm) 1 2 4
Swelling
None 9 1 0
Mild (<3 mm) 6 2 4
Moderate (≥3 mm, <20 mm) 1 6 5
Severe (≥20 mm) 0 5 7
Duration (after 1st dosing)
Warmth
0~3 day 2 4 4
4~6 day 1 1 1
Over 7 day 0 0 0
Erythema
0~3 day 1 5 6
4~6 day 1 3 5
Over 7 day 1 0 0
Swelling
0~3 day 1 5 10
4~6 day 1 6 3
Over 7 day 0 0 0
The intensity of each reaction is based on the maximum intensity experienced by each patient anytime during 
the whole study period. The information about reaction duration is based on the diary records collected during 
the first week of dosing.
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height SDS gain (LS mean ranging from 0.49 to 0.65) ob-
served during the 26-week study period was within the 
expected range, owing a 0–0.7 SDS gain over 1 year docu-
mented in a systematic review analyzing the effects of 
rhGH on short-term growth in children with ISS [4]. 
However, LB03002, administered at 0.5 mg/kg/week, 
failed to prove noninferiority to the control in terms of 
the HV change. The first plausible explanation is that the 
LB03002 dose (0.5 mg/kg/week) might not have been 
high enough to improve the HV of children with ISS. In 
the previous phase III trial of Korean GHD patients [15], 
HV achieved after administration of LB03002 at 0.5 mg/
kg/week was not inferior to that obtained with daily rhGH 
0.21 mg/kg/week. This implies that a higher dose (0.7 mg/
kg/week) of LB03002 should be considered for children 
with ISS. The other potential explanation is that the num-
ber of patients per group was too small to balance indi-
vidual variability inherent to the heterogenous genetic 
makeup of the ISS population [29].
Overall, the adverse event rate was higher in the 
LB03002 groups than in the controls; however, the fre-
quency of adverse drug reactions (ADRs) was low (4 pa-
tients in the LB03002 groups had a total of 8 ADRs), and 
most ADRs (7/8) were classified as mild. Also, injection 
site reactions were more common in the LB03002 groups, 
but usually resolved within 3–6 days since the onset, and 
the injection site pain caused by LB03002 waned within 
2–3 days. The severity of pain in all three groups tended 
to decrease with repeated dosing, which implies that the 
patients tolerated well either the daily or the weekly regi-
men. Moreover, high treatment compliance (≥80%) 
across all three groups suggests that the intensity of local 
reactions, among them pain, was not clinically significant 
and did not prevent the patients from following the treat-
ment regimen. Therefore, the safety profiles of LB03002 
at both doses administered to children with ISS for 26 
weeks were assessed to be acceptable and comparable 
with that of the control. Meanwhile, favorable long-term 
(2–3 years) safety data of LB03002 can be referenced both 
from the phase II/III [26] and phase III [16] studies con-
ducted in GHD children.
Some cautions should be taken while interpreting the 
results of this study. First, the annualized HV data were 
based on the height measurements taken at 6-month in-
tervals. Considering the potential seasonal variance of in-
dividual growth, the 1-year period would be ideal; how-
ever, 6 months were considered to be a minimum neces-
sary period for this type of study. Second, the safety profile 
of LB03002 in ISS patients was determined on the basis of 
a relatively short follow-up; thus, the safety of this agent 
needs to be verified in a longer time perspective, consid-
ering that rhGH treatment is typically administered for 
several years. Third, it should be remembered that diag-
nostic criteria for ISS vary from country to country; some 
authors recommend more stringent cutoff values for 
height SDS than those applied in this study (height SDS 
< –2.25 or even < –3.0) [30]. Finally, prescription of rhGH 
to otherwise healthy children, such as ISS patients, should 
be preceded by a systematic and critical evaluation of 
multiple factors, e.g., social well-being, functional impact, 
and economic burden, rather than solely a height gain 
[31, 32]. All these factors need to be considered in future 
studies of LB03002.
In conclusion, the once-weekly regimen of LB03002 
0.7 mg/kg demonstrated noninferiority to the daily-di-
vided regimen of rhGH 0.37 mg/kg/week in terms of HV 
increments. A 26-week treatment contributed to a sig-
nificant increase in auxological variables (HV, height 
gain, and height SDS) and concomitant changes in PD 
markers. Both doses of LB03002 were well tolerated and 
their safety profiles were comparable with that of daily 
rhGH. A confirmatory efficacy study needs to be under-
taken with LB03002 0.7 mg/kg/week in children with ISS.
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